How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Tyrosine kinase inhibitors (TKIs)
From the registry record2 judgments on this linkAll judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Nov 1 | Pembrolizumabmade here | Claude Opus 5.5 | Background | Current |
| Nov 2 | Lenvatinibmade here | Claude Opus 5.5 | Background | Current |
| Nov 3 | Tyrosine kinase inhibitors (TKIs) | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Albumin-Bound Paclitaxel | Claude Opus 5.5 | Background | Current |
| Nov 3 | Trastuzumab | Claude Opus 5.5 | Background | Current |
| Nov 3 | Pyrotinib | Claude Opus 5.5 | Background | Current |
| Nov 3 | INT008936 | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Goserelin | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Pertuzumab | Claude Opus 5.5 | Background | Replaced |
| Nov 3 | Docetaxel | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Iparomlimab | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Tuvonralimab | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Cadonilimab | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Alpelisib | Claude Opus 5.5 | Tested | Replaced |
| Nov 3 | Fulvestrant | Claude Opus 5.5 | Tested | Replaced |
| Nov 3 | PARP inhibitors | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Enfortumab vedotin | Claude Opus 5.5 | Tested | Replaced |
| Nov 3 | INT010594 | Claude Opus 5.5 | Background | Current |
| Nov 3 | Olaparibmade here | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Pertuzumab | Claude Opus 5.5 | Background | Current |
| Nov 3 | Niraparibmade here | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Trastuzumab deruxtecanmade here | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Palbociclibmade here | Claude Opus 5.5 | Tested | Current |
| Nov 3 | Abemaciclibmade here | Claude Opus 5.5 | Background · option | Current |
| Nov 3 | Alpelisib | Claude Opus 5.5 | Background · option | Current |
| Nov 3 | Fulvestrant | Claude Opus 5.5 | Background · option | Current |
| Nov 3 | Sacituzumab govitecanmade here | Claude Opus 5.5 | Background · option | Current |
| Nov 10 | Enfortumab vedotin | Claude Opus 5.5 | Tested | Current |
| Nov 10 | Anastrozolemade here | Claude Opus 5.5 | Background · option | Current |
| Nov 10 | Exemestanemade here | Claude Opus 5.5 | Background · option | Current |
| Nov 10 | Entrectinibmade here | Claude Opus 5.5 | Tested | Current |
| Nov 18 | Tyrosine kinase inhibitors (TKIs) | Rule based · role rule | Tested | Agrees |
| Nov 18 | Albumin-Bound Paclitaxel | Rule based · role rule | Tested | Overridden |
| Nov 18 | Trastuzumab | Rule based · role rule | Tested | Overridden |
| Nov 18 | Pyrotinib | Rule based · role rule | Tested | Overridden |
| Nov 18 | INT008936 | Rule based · role rule | Tested | Overridden |
| Nov 18 | Goserelin | Rule based · role rule | Tested | Overridden |
| Nov 18 | Pertuzumab | Rule based · role rule | Tested | Overridden |
| Nov 18 | Docetaxel | Rule based · role rule | Tested | Agrees |
| Nov 18 | Iparomlimab | Rule based · role rule | Tested | Agrees |
| Nov 18 | Tuvonralimab | Rule based · role rule | Tested | Agrees |
| Nov 18 | Cadonilimab | Rule based · role rule | Tested | Agrees |
| Nov 18 | Alpelisib | Rule based · role rule | Tested | Overridden |
| Nov 18 | Fulvestrant | Rule based · role rule | Tested | Overridden |
| Nov 18 | PARP inhibitors | Rule based · role rule | Tested | Agrees |
| Nov 18 | Enfortumab vedotin | Rule based · role rule | Tested | Agrees |
| Nov 18 | INT010594 | Rule based · role rule | Tested | Overridden |
| As of now | Salivary Gland Neoplasms | Rule based · main-condition rule | Main condition | Current |
The rules, in plain words
“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.
Which drugs a study tests
Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.
Where the whole record has been read, that reading's answer replaces the rule's.
What a study is mainly about
Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.
Checked against studies judged one by one; the study page says when it differs from the registry.